Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00365846 · ClinicalTrials.gov registry record · Phase 2
"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"
A Phase 2 study of Renal Transplant, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00365846 is a Phase 2 study of Renal Transplant that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 29 participants, below the 46-participant average among 5 other Renal Transplant trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00365846, a Phase 2 study of Renal Transplant, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to see if campath-1H can be used in first time renal transplant subjects to prevent rejection and reduce the overall amount of anti-rejection medications that patients take on a daily basis.
Conditions Studied
Interventions
- DRUG Campath-1H
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2000-08 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00365846
The ClinicalTrials.gov registry entry for NCT00365846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 46-participant average among 5 other Renal Transplant trials with a reported enrollment target (37% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Transplant appearing as the primary indexed condition, and to 1 intervention - of which Campath-1H is the first listed.
NCT00365846 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00365846 about?
NCT00365846 is a clinical study titled ""A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"". The purpose of the study is to see if campath-1H can be used in first time renal transplant subjects to prevent rejection and reduce the overall amount of anti-rejection medications that patients take on a daily basis.
What is the current status of trial NCT00365846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2000-08. Estimated completion is 2006-07.
What conditions does trial NCT00365846 study?
This clinical trial studies the following conditions: Renal Transplant.
What interventions are being tested in trial NCT00365846?
The interventions under investigation include: Campath-1H (DRUG).
Who is sponsoring clinical trial NCT00365846?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00365846 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
ACTIVE NOT RECRUITING · Phase 2
-
Cognitive Outcomes in Stable Renal Transplant Patients Switched FromTacrolimus to Envarsus XR™
ACTIVE NOT RECRUITING · Phase 4
-
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)
COMPLETED
-
Pilot Study for HLA Identical Living Donor Renal Transplant Recipients
COMPLETED · Phase 4
-
The Use of ACE Inhibitors in the Early Renal Post-transplant Period
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.